m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02271)
Name
Triprolidine
Synonyms
Actidil; Actidilat; Entra; Histafed; Myidyl; Tripolidina; Triprolidin; Triprolidinum; Venen; Triprolidine HCL; Triprolidine Monohydrochloride; Triprolidine hydrochloride; Triprolidine hydrochloride anhydrous; T 6764; Actidil (TN); Myidil (TN); Pro-Actidil; Pro-Entra; Tripolidina [INN-Spanish]; Triprolidine (INN); Triprolidine Hydrochloride (anhydrous); Triprolidine Monohydrochloride, Monohydrate; Triprolidine [INN:BAN]; Triprolidinum [INN-Latin]; Venen (TN); Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine; Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride; Trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene; Trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene; Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, monohydrochloride, monohydrate, stereoisomer; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, monohydrochloride; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl)-, hydrochloride (1:1); (E)-2-(1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)pyridine; (E)-2-[3-(1-Pyrrolidinyl)-1-p-tolylpropenyl]pyridine hydrochloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ium-1-ylprop-1-enyl]pyridine chloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine hydrochloride
    Click to Show/Hide
Status
Approved
Structure
Formula
C19H22N2
InChI
1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+
InChIKey
CBEQULMOCCWAQT-WOJGMQOQSA-N
PubChem CID
5282443
VARIDT Drug ID
DR01395
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Triprolidine. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Triprolidine through regulating the expression of P-glycoprotein 1 (ABCB1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Triprolidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Triprolidine through regulating the expression of P-glycoprotein 1 (ABCB1). [2], [3]
References
Ref 1 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 2 Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. Drug Metab Dispos. 2007 Aug;35(8):1341-9.
Ref 3 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.